Carlo Mulas

1.1k total citations
19 papers, 871 citations indexed

About

Carlo Mulas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Carlo Mulas has authored 19 papers receiving a total of 871 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Otorhinolaryngology. Recurrent topics in Carlo Mulas's work include Lung Cancer Research Studies (7 papers), Head and Neck Cancer Studies (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Carlo Mulas is often cited by papers focused on Lung Cancer Research Studies (7 papers), Head and Neck Cancer Studies (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Carlo Mulas collaborates with scholars based in Italy, United States and Japan. Carlo Mulas's co-authors include Antonio Macciò, Clelia Madeddu, Giovanni Mantovani, Giulia Gramignano, Elena Massa, Maria Caterina Mudu, C. Floris, Loredana Mura, Maria Rita Lusso and Itaru Omoto and has published in prestigious journals such as International Journal of Cancer, The Oncologist and Gynecologic Oncology.

In The Last Decade

Carlo Mulas

19 papers receiving 849 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carlo Mulas Italy	11	344	246	221	134	121	19	871
Maria Caterina Mudu Italy	10	233 0.7×	125 0.5×	179 0.8×	60 0.4×	92 0.8×	15	582
Andreas Stadlmayr Austria	17	211 0.6×	158 0.6×	156 0.7×	164 1.2×	230 1.9×	31	1.2k
Wei‐Zhong Ying United States	22	192 0.6×	90 0.4×	522 2.4×	137 1.0×	309 2.6×	45	1.2k
Philipp Rein Austria	21	223 0.6×	129 0.5×	266 1.2×	65 0.5×	30 0.2×	69	1.3k
D Cirillo Italy	13	87 0.3×	95 0.4×	185 0.8×	33 0.2×	39 0.3×	30	631
Gloria Rashid Israel	16	156 0.5×	99 0.4×	177 0.8×	44 0.3×	158 1.3×	39	1.0k
Kazuhiko Funabïki Japan	20	112 0.3×	51 0.2×	236 1.1×	75 0.6×	54 0.4×	60	1.1k
Julius F.W. Baller Netherlands	15	163 0.5×	174 0.7×	328 1.5×	22 0.2×	70 0.6×	27	1.1k
C Ghosh United States	7	265 0.8×	338 1.4×	233 1.1×	17 0.1×	56 0.5×	7	736
Massimo Ghiani Italy	11	204 0.6×	147 0.6×	97 0.4×	16 0.1×	45 0.4×	28	521

Countries citing papers authored by Carlo Mulas

Since Specialization

Citations

This map shows the geographic impact of Carlo Mulas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlo Mulas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlo Mulas more than expected).

Fields of papers citing papers by Carlo Mulas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlo Mulas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlo Mulas. The network helps show where Carlo Mulas may publish in the future.

Co-authorship network of co-authors of Carlo Mulas

This figure shows the co-authorship network connecting the top 25 collaborators of Carlo Mulas. A scholar is included among the top collaborators of Carlo Mulas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlo Mulas. Carlo Mulas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Macciò, Antonio, Clelia Madeddu, Giulia Gramignano, et al.. (2014). The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica. 100(1). 124–132. 172 indexed citations

Macciò, Antonio, Clelia Madeddu, Giulia Gramignano, et al.. (2011). A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: Evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecologic Oncology. 124(3). 417–425. 102 indexed citations

Macciò, Antonio, Clelia Madeddu, Giulia Gramignano, et al.. (2010). Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. Journal of Molecular Medicine. 88(7). 677–686. 81 indexed citations

Macciò, Antonio, et al.. (2010). Efficacy and Safety of Oral Lactoferrin Supplementation in Combination with rHuEPO-β for the Treatment of Anemia in Advanced Cancer Patients Undergoing Chemotherapy: Open-Label, Randomized Controlled Study. The Oncologist. 15(8). 894–902. 47 indexed citations

Mulas, Carlo, et al.. (2004). Feasibility of high-dose interferon-α2b adjuvant therapy for high-risk resected cutaneous melanoma. Melanoma Research. 14(2). S1–S7. 2 indexed citations

Mantovani, Giovanni, Antonio Macciò, Clelia Madeddu, et al.. (2002). Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. Oncology Reports. 9(4). 887–96. 16 indexed citations

Mantovani, Giovanni, Antonio Macciò, Carlo Mulas, et al.. (2002). Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer. Oncology Reports. 9(3). 661–70. 9 indexed citations

Mantovani, Giovanni, E Proto, Elena Massa, et al.. (2002). Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: A phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. International Journal of Oncology. 20(2). 419–27. 13 indexed citations

Mantovani, Giovanni, Antonio Macciò, Clelia Madeddu, et al.. (2001). Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. Journal of Molecular Medicine. 79(7). 406–414. 71 indexed citations

10.

Mantovani, Giovanni, Antonio Macciò, Clelia Madeddu, et al.. (2001). Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: Correlation with stage and performance status. International Journal of Cancer. 98(1). 84–91. 128 indexed citations

11.

Macciò, Antonio, Clelia Madeddu, Elena Massa, et al.. (2001). Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy. International Journal of Oncology. 18(2). 383–91. 9 indexed citations

12.

Macciò, Antonio, P. Lai, Elena Massa, et al.. (2000). Results of a Dose-Intense Phase 1 Study of a Combination Chemotherapy Regimen With Cisplatin and Epidoxorubicin Including Medroxyprogesterone Acetate and Recombinant Interleukin-2 in Patients With Inoperable Primary Lung Cancer. Journal of Immunotherapy. 23(2). 267–274. 11 indexed citations

13.

Mantovani, Giovanni, Antonio Macciò, Loredana Mura, et al.. (2000). Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. Journal of Molecular Medicine. 78(10). 554–561. 166 indexed citations

14.

Mantovani, Giovanna, Antonio Macciò, Elena Massa, et al.. (2000). Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical outcome, toxicity and organ/function preservation.. International Journal of Oncology. 16(6). 1227–33. 10 indexed citations

15.

Mantovani, Giovanna, Antonio Macciò, Elena Massa, et al.. (2000). Results of a dose-intense phase II study of a combination chemotherapy regimen with cisplatin (CDDP) and epirubicin (EPI) including medroxyprogesterone acetate (MPA) and recombinant interleukin 2 (rIL-2) in patients with inoperable primary lung cancer. Lung Cancer. 29(1). 53–53. 1 indexed citations

16.

Macciò, Antonio, et al.. (2000). Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.. PubMed. 19(4C). 3495–502. 7 indexed citations

17.

Mantovani, Giovanna, Antonio Macciò, Elena Massa, et al.. (1999). Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical response and organ/function preservation.. Oncology Reports. 6(6). 1425–30. 1 indexed citations

18.

Mantovani, Giovanni, Vittorio Gebbia, Mario Airoldi, et al.. (1998). Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2. Cancer Immunology Immunotherapy. 47(3). 149–156. 17 indexed citations

19.

Mantovani, Giovanna, Massimo Ghiani, P. Lai, et al.. (1998). Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.. Oncology Reports. 5(6). 1499–505. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact